Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian C Shook

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
ACS Chemical Neuroscience|September 10, 2014
JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's diseaseJohn R Atack, Brian C Shook, Stefanie Rassnick, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2010
Methylene amine substituted arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonistsBrian C Shook, Stefanie Rassnick, Daniel Hall, et al.
Journal of Medicinal Chemistry|January 14, 2012
Design and characterization of optimized adenosine A₂A/A₁ receptor antagonists for the treatment of Parkinson's diseaseBrian C Shook, Stefanie Rassnick, Nathaniel Wallace, et al.
Journal of Medicinal Chemistry|October 27, 2010
In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's diseaseBrian C Shook, Stefanie Rassnick, Melville C Osborne, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2010
Optimization of arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonistsBrian C Shook, Stefanie Rassnick, Devraj Chakravarty, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
ACS Chemical Neuroscience|September 10, 2014
JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's diseaseJohn R Atack, Brian C Shook, Stefanie Rassnick, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2010
Methylene amine substituted arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonistsBrian C Shook, Stefanie Rassnick, Daniel Hall, et al.
Journal of Medicinal Chemistry|January 14, 2012
Design and characterization of optimized adenosine A₂A/A₁ receptor antagonists for the treatment of Parkinson's diseaseBrian C Shook, Stefanie Rassnick, Nathaniel Wallace, et al.
Journal of Medicinal Chemistry|October 27, 2010
In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's diseaseBrian C Shook, Stefanie Rassnick, Melville C Osborne, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2010
Optimization of arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonistsBrian C Shook, Stefanie Rassnick, Devraj Chakravarty, et al.
Pageof 2